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AbsTrACT
Objectives To assess the prevalence of antiepileptic 
drug (aeD) exposure in pregnant women and the 
comparative risk of terminations of pregnancy (TOps), 
spontaneous abortions, stillbirths, major birth defects 
(MBDs), neonatal distress and small for gestational 
age (sGa) infants following intrauterine aeD exposure 
in the emilia Romagna region, Italy (4 459 246 
inhabitants on 31 December 2011).
Methods We identified all deliveries and 
hospitalised abortions in emilia Romagna in the 
period 2009–2011 from the certificate of delivery 
assistance registry (certificato di assistenza al 
parto— cedap) and the hospital discharge card 
registry, exposure to aeDs from the reimbursed 
drug prescription registries, MBDs from the regional 
registry of congenital malformations, and apgar 
scores and cases of sGa from the cedap. Records 
from different registries were linked. 
results We identified 145 243 pregnancies: 111 284 
deliveries, 16 408 spontaneous abortions and 17 551 
TOps. six hundred and eleven pregnancies (0.42%; 
95% cl 0.39 to 0.46) were exposed to aeDs. In the 
aeD-exposed group 21% of pregnancies ended 
in TOps vs 12% in the non-exposed women (OR: 
2.24; 95% cI 1.41 to 3.56). Rates of spontaneous 
abortions, stillbirths, neonatal distress and sGa were 
comparable. Three hundred and fifty-three babies 
(0.31%; 95% cI 0.28 to 0.35) were exposed to aeDs 
during the first trimester. MBD rates were 2.3% in 
the exposed vs 2.0% in the non-exposed pregnancies 
(OR: 1.12, 95% cI 0.55 to 2.55). 
Conclusion The emilia Romagna prevalence of aeD 
exposure in pregnancy was 0.42%, comparable with 
previous european studies. Rates of spontaneous 
abortions, stillbirths, neonatal distress, sGa and 
MBDs following aeD exposure were not significantly 
increased. The rate of TOps was significantly higher in 
the aeD-exposed women.
InTrOduCTIOn
The reported rate of antiepileptic drug (AED) 
use in pregnant women is 0.2%–2.2%, with a 
possible rising trend due to the increasing use 
of these medications for indications other than 
epilepsy.1–7 Exposure to older generation AEDs 
during the first trimester has been consistently 
associated with an approximately twofold to 
threefold increased risk of major birth defects 
(MBDs),8 whereas data on most of the newer 
AEDs are still insufficient. A slightly higher risk 
of being small for gestational age (SGA) or low 
birth weight has been reported in AED-exposed 
babies, but not consistently.5 9–15 Although several 
studies have reported no increase in spontaneous 
abortions in women with epilepsy,16 17 others have 
found a higher frequency associated with AED 
therapy and a family history of MBDs.18 19 Data 
on stillbirths in women with epilepsy range from 
an incidence comparable with that of the general 
population20 to a twofold increase.21 A popula-
tion study found that preterm deliveries were 
more common in women using AEDs, but only 
for indications other than epilepsy.5 Although the 
risk of adverse fetal events appears to be linked 
primarily to the use of AEDs, the indication of 
use could therefore play a role.22 Few data are 
available on induced abortions in women with 
epilepsy or exposed to AEDs.17 
Only very rarely can therapy be withdrawn for 
pregnancy in epilepsy and psychiatric disorders, 
making it essential to choose the safest substances 
for the woman and her offspring. Currently the 
main sources of data on AED safety in pregnancy 
are pregnancy registries. Although these regis-
tries have led to a vast increase in the informa-
tion available on the topic, they have several 
selection biases, being based on voluntary enrol-
ment and including mainly women with epilepsy, 
mostly lacking comparison with an AED-unex-
posed population. Population-based studies can 
address many of these limits, offering a major 
complementary source of information. Since 
2010 several population-based studies have been 
published mainly from northern Europe, while 
data from other countries are scant.
We performed a retrospective observational 
population-based study in an Italian region to assess 
AED exposure and safety in pregnancy.

















To protect patient privacy, all data were anonymised at regional 
level by the data owner in accordance with Italian legislation.
study population
We identified all women residents in Emilia Romagna, a northern 
Italian region of 4 459 246 inhabitants on 31 December 2011,23 
who had a delivery or underwent an abortion in a hospital in 
Emilia Romagna, between 1 January 2009 and 31 December 
2011. The women were identified using two administrative 
databases: the certificate of delivery assistance (Certificato di 
Assistenza al Parto—CedAP) and the hospital discharge card 
(Scheda di Dimissione Ospedaliera  (SDO)). The CedAP collects 
all deliveries including stillbirths, defined as fetal deaths after the 
23rd week of gestation, and covered >99% of births during the 
studied period. The SDO collects the International Classification 
of Diseases (ICD-9) codes of all discharge diagnoses from hospi-
tals, including spontaneous abortion, covering approximately all 
abortions occurring in inpatients and terminations of pregnancy 
(TOPs), covering 64.6% of TOPs (the incomplete coverage 
being due to adjustment to a new national privacy policy during 
the study period). Both databases identify the subject by a unique 
anonymous code allowing the information to be linked with the 
other regional administrative databases.
Exposure to AEds
In Italy, AEDs are reimbursed by the National Health Service. 
All prescriptions are recorded in prescription databases, which 
in Emilia Romagna have had complete coverage since 2009. All 
prescriptions for the following AEDs were selected: phenobar-
bital, primidone, phenytoin, ethosuximide, clonazepam, carba-
mazepine, oxcarbazepine, rufinamide, valproic acid, vigabatrin, 
tiagabine, lamotrigine, felbamate, topiramate, gabapentin, leve-
tiracetam, zonisamide, pregabalin and lacosamide. For the deliv-
eries cohort, two exposure periods were considered based on 
the date of delivery and gestational age: the pregnancy period 
and the first trimester. For the abortions cohort, the trimester 
preceding the event was fixed by consensus among the authors as 
the AED exposure period in pregnancy, the gestational age being 
unavailable. For each woman, the average daily dose was calcu-
lated as the ratio between the total amount of drug prescribed 
during the observation period and the number of observed days.
stratification according to clinical indication
As the prescription databases in Italy do not contain informa-
tion on clinical indications, this was assessed using an algorithm 
designed and validated ad hoc for AED prescriptions (methods 
described elsewhere).24 This tool distinguishes between women 
receiving AEDs for epilepsy and those taking AEDs for psychi-
atric disorders, by far the most common indications for the use 
of AEDs in pregnancy, using exclusively AED prescriptions.
Identification of Mbds
We identified all the MBDs reported to the Emilia Romagna 
Registry of Congenital Malformations (IMER), which 
covers >95% of all births including stillbirths of 26 weeks 
or more. Reporting is made by paediatricians during the first 
week of the infant’s life. A further contribution to the registry, 
consisting of MBDs detected during the first year of life, was 
taken directly from the hospital discharge cards. Each case is 
coded using a British Paediatric Association modification of the 
WHO’s ICD system.25 IMER records were linked to the CedAP, 
and consequently to all the other records of the mothers, using 
the following information: place of birth, child’s date of birth, 
maternal date of birth and maternal residence.
Infant health
Cases of SGA infants and Apgar scores were taken from the 
CedAP. SGA was defined as birth weight below the 10th percen-
tile of the gender-specific birth weight for gestational age refer-
ence curves of the Italian population.26 An Apgar score between 
1 and 3 was considered to indicate severe fetal distress, while an 
Apgar score between 4 and 6 indicated moderate distress. The 
exposure period considered was the entire pregnancy.
Identification of confounding factors
The following factors were considered confounders for TOPs: 
maternal age (drawn from the SDO), and prescriptions for drugs 
belonging to the Food and Drug Administration pregnancy cate-
gories X (contraindicated in pregnancy) and D (positive evidence 
of risk) (from the prescription registries). Educational level and 
smoking habit were unavailable for this population.
The following factors were considered confounders for 
MBDs: maternal age, educational level, smoking habit (from 
the CedAP), and maternal and fetal diseases that could affect 
pregnancy outcome (from diagnosis recorded in SDO database 
or prescriptions as disease proxies: hypertension, eclampsia and 
pre-eclampsia, diabetes, familial genetic disease, presumed fetal 
lesion from viral or other kind of maternal disease, and all anti-
hypertensive and antidiabetic drugs).
The following factors were considered confounders for SGA: 
maternal age and smoking habit, twin pregnancy (from the 
CedAP), hypertension and diabetes.
statistical analysis
Daily dose of AED was presented as mean (SD) and median 
(IQR). Categorical variables were presented as absolute (n) and 
relative frequency (%).
Fisher’s exact test was use to evaluate the relation between 
potential confounders, exposures and outcomes (data not 
shown). Univariate and multivariate logistic regression analyses, 
adjusted for confounders, were performed to study the associa-
tion between outcomes (TOPs, MBDs, SGA, Apgar score) and 
exposure to AEDs in two periods (pregnancy and first trimester), 
using the variable as dichotomic and categorical (no AED, one 
AED, more AEDs). The results are presented as OR and 95% CI. 




Our study included 145 243 pregnancies: 111 284 deliveries (278 
stillbirths), 16 408 spontaneous abortions and 17 551 TOPs. Out 
of all deliveries, 2516 (2.2%), corresponding to 2555 newborns, 
were excluded because of non-univocal registry linkage.
Exposure to AEds
Six hundred and eleven women (0.42%; 95% CI 0.39 to 0.46) 
were exposed to AEDs during pregnancy: 537 to one AED, 74 to 
more than one. The average daily doses of the active substances 
are listed in table 1. No woman was exposed to rufinamide, tiag-
abine, felbamate or lacosamide. The mean age was 32.5 years 
(range 12–54) vs 31.9 (16–48) of the non-exposed.
Three hundred and fifty three babies (0.31%; 95% CI 0.28% 
to 0.35%) were exposed to AEDs during the first trimester: 321 
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to one AED, 32 to more than one. The proportion of newborns 
exposed to each active substance, in mono or polytherapy, is 
shown in figure 1. According to the algorithm, the maternal indi-
cation for AEDs was epilepsy in 295 cases (83.6%).
Pregnancy outcomes
Table 2 shows the outcome of the 145 243 pregnancies in the 
AED-exposed and non-exposed women.
The risk of TOP was significantly increased after exposure 
to AEDs. When spontaneous abortions were excluded from the 
analysis, pregnancies ended in TOP in 23.7% of the AED-ex-
posed women vs 13.6% of the unexposed (OR 1.97; CI 1.62 
to 2.40) with a positive relation to the number of AEDs taken, 
as shown in table 3. According to the algorithm among the 128 
women exposed to AEDs, 57 had epilepsy (44.5%), 39 a psychi-
atric disorder (30.4%) while for 32 (25%) the algorithm was 
not applicable (no exposure from 12 to 6 months before the 
event).24
Major birth defects
During the 3-year observational period, 2302 cases of newborns 
with MBDs were reported: 1928 from paediatricians’ reports 
during the first week and 374 from hospital discharge cards 
during the first year of life. Eight babies with MBDs proved to 
have been exposed to AEDs during the first trimester of preg-
nancy. The incidence of MBDs was 2.3% in the newborns from 
exposed mothers (first trimester) and 2.0% in the newborns from 
non-exposed mothers (OR 1.12; CI 0.55 to 2.55). The risk of 
MBDs slightly increased when the mother was exposed to more 
than one AED; however, this was not significant, as reported in 
table 4.
The specific MBDs reported in the AED-exposed group are 
listed in table 5. All eight MBDs were reported by paediatricians 
during the first week of life. The only abnormality to occur in 
more than one baby was ventricular septal defect, which had a 
prevalence of 84.98 per 10 000 liveborns in the exposed popula-
tion vs 33.81 per 10 000 liveborns in the non-exposed. The drug 
to which these babies were exposed was gabapentin in two cases 
and pregabalin in the third. Table 4 also reports the supposed 
diagnosis according to the algorithm.
Infant health
There were 34 cases of SGA (8.2%) in exposed infants and 7899 
(7%) in non-exposed babies (OR 1.18; CI 0.83 to 1.68). Even 
Table 1 Daily doses of antiepileptic drugs during the first trimester or trimester preceding abortion (mg/day)
Active substance Mean sd Median First quartile Third quartile n
Phenobarbital 97.2 43.4 94.4 66.7 133.3 44
Clonazepam 1.1 1.4 0.6 0.3 1.4 85
Carbamazepine 540.6 370.2 444.4 266.7 800.0 120
Oxcarbazepine 639.8 443.3 500.0 333.3 666.7 31
Valproate 508.8 385.4 366.7 200.0 666.7 116
Valpromide 800.0 565.7 800.0 400.0 1200 2
Lamotrigine 214.1 222.3 124.5 62.2 248.9 99
Topiramate 136.7 188.1 66.7 33.3 133.3 30
Levetiracetam 1556 1026 1333 1000 2000 33
Zonisamide 118.6 68.8 132.2 73.9 163.3 4
Figure 1 exposure to antiepileptic drugs in the first trimester (on the top of each column the number of exposed newborns is reported). cBZ, 
carbamazepine; cNZ, clonazepam; eTs, ethosuximide; GBp, gabapentin; LeV, levetiracetam; LTG, lamotrigine; OXc, oxcarbazepine; pB/pRI, phenobarbital/
primidone; pGB, pregabalin; TpM, topiramate; Vpa, valproic acid; ZNs, zonisamide. 
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considering polytherapy the rate was not significantly increased; 
indeed it was 6.8% (OR 0.97; CI 0.30 to 3.14).
The only single drug for which a significant increase in 
SGA was found was gabapentin, as we have reported else-
where.27 Confounding factors, that is, maternal age (<20 years 
and >37 years) and smoking habit, twin pregnancy, hyperten-
sion and diabetes, did not affect the result.
The Apgar scores did not differ significantly in AED-exposed 
and non-exposed infants: an Apgar score between 1 and 3 (severe 
fetal distress) was attributed to none of the exposed and to 0.1% 
of the non-exposed babies, an Apgar score between 4 and 6 
(moderate distress) was attributed to 1% of the exposed and 
0.5% of the non-exposed infants, and an Apgar score between 
7 and 10 (normal) was attributed to 99% of the exposed and 
99.4% of the non-exposed babies (P=0.317, Fisher’s exact test).
dIsCussIOn
To our knowledge, this is the first study in a southern Euro-
pean country to explore the use of AEDs in pregnancy and their 
possible adverse consequences.
The frequency of AED use in the first trimester of pregnancy 
in our population, 4 per 1000 pregnancies, or 3.1 per 1000 
deliveries, is comparable with the data reported elsewhere.1–3 5 7
Carbamazepine was the most used anticonvulsant in Emilia 
Romagna during the study period, being taken in 23% of all the 
exposed pregnancies. This differed from reports from Denmark 
and the USA,5 7 where lamotrigine was the most prescribed drug 
in pregnancy during the same period. Levetiracetam was much 
less used in our population (5.9% of the total used AEDs) than 
in studies referring to similar periods of time in other European 
countries and the USA.5 7 28 29 A striking finding of our study is 
that approximately one in five AED users was taking valproate, a 
drug currently considered the most hazardous anticonvulsant in 
pregnancy due to its higher teratogenic risk and possible detri-
mental cognitive and developmental effects.30–33 One possible 
explanation for the unexpected over-representation of valproate 
is that it is used both in epilepsy and in psychiatric disorders. 
Indeed, one study investigating trends of use of antiepileptic 
agents in pregnant women showed that over time valproate use 
decreased overall, but not in patients with a psychiatric disorder.7 
According to our algorithm, 30% of the valproate-exposed 
patients suffered from psychiatric disorders. Moreover, taking 
into account the limitations of the ascertainment methods, 
the mean dose of valproate in our population (approximately 
500 mg/day) should be considered low, associated with a lower 
risk.30 No MBDs were reported in these patients, but the cohort 
is too small to draw any conclusion. Lastly, our data refer to a 
period preceding the strict recommendations on valproate use in 
women of childbearing potential.34 35
In agreement with most of the literature data, the rates of 
spontaneous abortions and stillbirths were not increased in the 
antiepileptic-exposed women.16 17 20
One limitation of our study is that due to the current Italian 
privacy policy, the ascertainment of pregnancy terminations did 
not cover all the hospitals in Emilia Romagna. Compared with 
data from the Italian National Institute for Statistics (ISTAT), to 
which all TOP figures were transmitted anonymously and not 
linkable to the other registries, the coverage was 64.6%.36 We 
consider that the incomplete coverage of terminations did not 
significantly affect our results as there is no reason to assume 
that in some hospitals women taking anticonvulsants were more 
represented among women undergoing an abortion.
Taking these limits into account, the most original finding 
of our study is the clear-cut higher risk of induced abortion in 
women taking AEDs, with a trend towards an increased risk 
when more than one drug is used. A possible explanation could 
be an excess number of birth defects in the exposed fetuses 
detected by prenatal ultrasound. This would indicate that 
studies on malformations detected exclusively on delivery are 
not completely reliable. Unfortunately, no further information 
was available on the abortions, including the clinical indica-
tion. This, however, is unlikely to be the main explanation as 
second trimester abortions (allowed in Italy only for severe fetal 
or maternal pathologies) accounted for 3.5% of all terminations 
during that period in Emilia Romagna (ISTAT36). Accordingly, 
the only other report to our knowledge on induced abortions in 
women taking anticonvulsants showed only a slight increase not 
accounted for by fetal disease.17 According to our algorithm, the 
rate of women with psychiatric disorders was higher in the TOP 
population than in the one of women who gave birth to a child. 
Interestingly, data from northern European population-based 
studies show that women on antipsychotics and antidepressants 
had a significantly increased risk of induced abortion, which was 
associated with mental health rather than fetal malformations, 
also considering only late terminations.37–39 On the other hand, 
physicians caring for women with epilepsy, including several 
members of the ESPEA group (BM, FB, RDA, PT, LL, IN), report 
that faced with an unplanned pregnancy, a significant number of 
women opt for TOP very early due to a groundless fear of the 
pregnancy outcome. These ‘unnecessary’ abortions are the result 
of a malpractice, which merits investigation. Further studies 
focused on both physicians’ attitudes and patients’ risk percep-
tion are needed to explain the excess number of terminations in 
this population.
The MBD rate in the antiepileptic-exposed population only 
slightly exceeded that in the non-exposed women: indeed, after 
adjusting for confounding factors the OR was 1. The small 
numbers preclude a discussion of the apparent trend towards 
a major risk of birth defects on polytherapy as only one patient 
out of 32 women exposed to polytherapy had a child with an 
MBD. Caution is needed in speculating on single AED or specific 
malformations due to the low number of MBDs. However, we 
found a significantly higher risk of ventricular septal defect, 
which had a more than twofold higher prevalence in the antie-
pileptic-exposed population. Interestingly, two out of the three 
Table 2 Antiepileptic drug exposure and pregnancy outcome
non-exposed Exposed
n % n %
Delivery 110 871 76.7 413 67.6
Stillbirth 278 0.2 1 0.3
Spontaneous abortion 16 338 11.3 70 11.5
Terminations of pregnancy 17 423 12.0 128 20.9
Total 144 632 100 611 100
Table 3 Risk of induced abortion per number of AEDs
AEds (n) n Events % Crude Or Adjusted Or*
0 128 294 17 423 13.6 1 1
1 479 110 23.0 1.90 (CI 1.53 to 
2.34)
1.55 (CI 1.24 to 
1.93)
>1 62 18 29.0 2.60 (CI 1.50 to 
4.50)
2.08 (CI 1.19 to 
3.64)
*Adjusted for maternal age, drugs belonging to X and D Food and Drug 
Administration pregnancy categories, antipsychotics, lithium and antidepressants.
AEDs, antiepileptic drugs.
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cases involved maternal exposure to gabapentin and in the third 
to pregabalin, a molecule with a similar chemical and phar-
macodynamic profile as we already reported elsewhere.27 In 
discussing our results on MBDs, several limitations, intrinsic to 
the methods we used, should be acknowledged. Birth defects 
are mainly ascertained during the first week of life. After that 
period, and until the first year of life, further information is 
added to the malformation registry only for in-hospital cases, as 
the source of information is the hospital discharge card. There-
fore a non-quantifiable, although limited, number of cases is lost. 
As an additional limit, we did not provide data on folic acid use 
and consequently on its possible association with the incidence 
of MBDs. In Italy only the folic acid dosage of 5 mg is reimburs-
able, while the most used 400 μg can be purchased as an over-
the-counter drug and is therefore untraceable. Furthermore, the 
reimbursable formulation is very inexpensive and therefore is 
often purchased with untraceable private prescriptions. As a 
further limit, information on the clinical indication could only 
be inferred using an algorithm created ad hoc while information 
on seizures in pregnancy was unavailable.
In agreement with some studies, we did not find a higher risk 
of SGA in infants exposed to AEDs,10 11 but different substances 
might have a different impact on fetal growth.14 15 In our 
population, gabapentin seems to carry a higher risk than other 
anticonvulsants.27
However, due to the rarity of MBDs and SGA infants, our 
study was underpowered to provide information on the risks 
associated with single AEDs. This is a crucial point given that 
the continuation of antiepileptic therapy during pregnancy is the 
safest solution in most cases, as seizure relapse during pregnancy 
is associated with increased maternal morbidity and mortality.40
The need for similar systems to monitor the safety of AEDs in 
pregnancy in a population-based context is evident, also consid-
ering that new anticonvulsants will be marketed in the coming 
years. For this reason, we suggest that reliable administrative data 
in existing European registries be pooled to obtain a sufficient 
statistical power to investigate each single antiepileptic agent.
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AED, antiepileptic drug; CBZ, carbamazepine; CNZ, clonazepam; Epi, epilepsy; 
ETS, ethosuximide; GBP, gabapentin; LTG, lamotrigine; MBD, major birth defects; 
PB, phenobarbital; PGB, pregabalin; Psy, psychiatric disorder.
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